GSK melanoma pill backed by UK cost watchdog with price cut

LONDON, Sept 18 (Reuters) - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.